During Friday’s current trade, Spectra Energy Corp (NYSE:SE)’s shares gained 0.15%, to $36.47.
Spectra Energy Corp (SE), Chief Executive Officer Greg Ebel will speak at the 2015 American Gas Association Financial Forum on Monday, May 18, 2015. Ebel also serves as chief executive officer of Spectra Energy Partners (SEP).
The presentation is planned to start at 1:00 p.m. PT and will be accessible via webcast.
Spectra Energy Corp, through its auxiliaries, owns and operates a portfolio of natural gas-related energy assets in North America. The company’s Spectra Energy Partners segment engages in the transmission, storage, and gathering of natural gas, in addition to transportation and storage of crude oil and natural gas liquids (NGLs) for customers in various regions of the midwestern, northeastern, and southeastern United States and Canada. Its natural gas pipeline systems comprise of about 21,000 miles of transmission pipelines; and storage capacity comprises 295 billion cubic feet (Bcf). Its Distribution segment offers natural gas storage, transmission, and distribution services for residential, commercial, and industrial customers in Canada.
The Western Union Company (NYSE:WU)’s shares dropped -1.59% to $21.61, during the current trading session Friday’s.
The Western Union Company (WU), declared that its board of directors declared a quarterly cash dividend of $0.155 per common share, payable June 30, 2015 to stockholders of record at the close of business on June 16, 2015.
The Western Union Company provides money movement and payment services worldwide. The company operates in three segments: Consumer-to-Consumer, Consumer-to-Business, and Business Solutions. The Consumer-to-Consumer segment offers cash money transfer services involving walk-in agent locations. This segment provides various options for sending and receiving funds, counting walk-in and telephone money transfer, online money transfer, and account based money transfer services through a network of third-party agents using multi-currency and real-time money transfer processing systems.
In an afternoon trade, State Street Corp (NYSE:STT)’s shares climbed 0.08%, to $77.78.
State Street Corp (STT), declared the release of its 2014 Corporate Responsibility (CR) report, which highlights the company’s commitment to economic development, environmental sustainability and social governance and engagement.
“Corporate responsibility is a fundamental part of our values and culture,” said Alison Quirk, executive vice president and chief human resources and citizenship officer. “We believe that the long-term success of our company is directly tied to positively impacting the communities where we live and work.”
Highlights of the 2014 corporate responsibility report comprise:
Environmental, Social and Governance
- State Street signed the United Nations Global Compact, a global initiative whose signatories share the conviction that responsible business practices contribute to a more stable, equitable and inclusive global market and assist build prosperous societies. By signing the compact, State Street committed to align its business operations and strategy with 10 universally accepted principles in the areas of human rights, labor, the environment and anti-corruption.
- In December 2014, State Street Global Advisors introduced the first low-carbon ETF product, LOWC. Developed in conjunction with the United Nations Joint Staff Pension Fund, LOWC is a new ETF that seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the MSCI ACWI Low Carbon Target Index.
- At the end of 2014, close to $220 billion in ESG assets were being managed on behalf of clients.
State Street Corporation provides a range of financial products and services to institutional investors worldwide. The company offers investment servicing products and services, counting custody; product- and participant-level accounting; daily pricing and administration; master trust and master custody; record-keeping; cash administration; foreign exchange, brokerage, and other trading services; securities finance; deposit and short-term investment facilities; loans and lease financing; investment manager and alternative investment manager operations outsourcing; and performance, risk, and compliance analytics. It also provides investment administration services, such as investment administration, investment research, and investment advisory services to corporations, public funds, and other sophisticated investors, in addition to offers active and passive asset administration strategies for equity, fixed-income, and cash asset classes.
Eli Lilly and Co (NYSE:LLY), during its Friday’s current trading session dwindled -0.40% to $72.78.
Eli Lilly and Co (LLY), and Sanford-Burnham Medical Research Institute recently declared that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit medical research institute, will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren’s Syndrome, inflammatory bowel disease and other autoimmune disorders.
The comprehensive research partnership is driven by Lilly’s world-class biotechnology capabilities and expertise in immunology, and Sanford-Burnham’s deep expertise in understanding the fundamental cellular pathways regulating the immune system focusing on the immune checkpoint networks. This high degree of interaction will allow the organizations to flexibly and efficiently advance projects to clinical investigation. The research partnershipwill be co-chaired by Thomas F. Bumol, Ph.D., senior vice president, biotechnology and immunology research at Lilly, and Carl Ware, Ph.D., director, Infectious and Inflammatory Diseases Center at Sanford-Burnham.
“Immunology is an important research area of focus for Lilly, and through this exciting partnership with Sanford-Burnham, our scientists can discover and develop new medicines together in a seamless way that takes advantage of each group in a family of key targets,” said Bumol.
Lilly has established its presence in immunology in recent years through its own R&D and collaborations, with seven molecules presently in the pipeline for conditions such as psoriasis, rheumatoid arthritis, lupus and inflammatory bowel disease. Sanford-Burnham’s work in this area focuses on cell communication pathways that control the development of lymphocytes, innate and adaptive immune responses, and inflammation. Their work has led to the discovery of molecular targets for the development of treatments for immunological and inflammatory diseases, and cancer.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
